Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Trastuzumab|DRUG: pertuzumab|DRUG: lapatinib
Sponsor: UNC Lineberger Comprehensive Cancer Center
Collaborators: Genentech, Inc.|Susan G. Komen Breast Cancer Foundation|GlaxoSmithKline